An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

555

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

December 31, 2008

Conditions
HIV Infection
Interventions
DRUG

TMC114

600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available

Trial Locations (64)

Unknown

Birmingham

Beverly Hills

La Jolla

Long Beach

Los Angeles

Oakland

San Francisco

Washington D.C.

Fort Lauderdale

Miami

Vero Beach

Atlanta

Macon

Chicago

Boston

Springfield

Camden

Albany

New York

Cincinnati

Hershey

Philadelphia

Dallas

Galveston

Seattle

Milwaukee

Buenos Aires

Darlinghurst

Melbourne

Perth

Vienna

Brussels

Ghent

Campinas

Curitiba

Rio de Janeiro

São Paulo

Calgary

Toronto

Montreal

Le Kremlin-Bicêtre

Montpellier

Nantes

Paris

Toulon

Villejuif

Berlin

Bonn

Düsseldorf

Essen

Freiburg im Breisgau

Hamburg

Kÿln

Mannheim

Munich

Budapest

Lisbon

Porto

Barakaldo Vizcaya S/N

Barcelona

Madrid

Edinburgh

London

Manchester

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00081588 - An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects. | Biotech Hunter | Biotech Hunter